Home Stocks Chinese regulators accept Zai Lab application for KarXT (ZLAB:NASDAQ)

Chinese regulators accept Zai Lab application for KarXT (ZLAB:NASDAQ)

by Deidre Salcido
0 comments
Image 1689585487.jpg

JHVEPhoto

Chinese regulators have accepted Zai Lab’s (NASDAQ:ZLAB) market application for the drug KarXT, also known as xanomeline and trospium chloride, for the treatment of schizophrenia in adults.

Zai Lab (NASDAQ:ZLAB) has an exclusive license from Bristol-Myers’ (BMY

You may also like

Leave a Comment

About Us

Welcome to AI Investor Picks, your trusted source for investment insights, financial strategies, and business opportunities. We are dedicated to providing cutting-edge information and analysis on a wide range of investment topics, including stockscryptocurrencyreal estate, finance, and much more.

© 2025 AI Investor Picks – All Rights Reserved

AI Investor Picks